European Journal of Heart Failure

Cover image for Vol. 19 Issue 7

Edited By: Prof. Marco Metra

Impact Factor: 6.968

ISI Journal Citation Reports © Ranking: 2016: 12/126 (Cardiac & Cardiovascular Systems)

Online ISSN: 1879-0844

Associated Title(s): ESC Heart Failure



Author Guidelines


xREQUIRED FORMS

European Journal of Heart Failure requests that all authors complete:
An ICMJE Conflicts of Interest disclosure form
An Author Contribution form

INTRODUCTION

Thank you for your interest in European Journal of Heart Failure. Please consult the following instructions for help in preparing your manuscript, and feel free to contact us with any questions. To ensure fast peer review and publication, manuscripts that do not adhere to the following instructions will be returned to the corresponding author for technical revision before undergoing peer review. We look forward to your submission.

AIMS AND SCOPE

The European Journal of Heart Failure is the international journal of the Heart Failure Association of the European Society of Cardiology dedicated to the advancement of knowledge in the field of heart failure. The journal publishes reviews and editorials in order to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as the clinical, social and population sciences all form part of the discipline that is heart failure. Accordingly, submission of manuscripts on basic, clinical and population sciences is invited. Original contributions on nursing, care of the elderly, primary care, health economics and other specialist fields related to heart failure are also welcome.

HEART NETWORK

The European Journal of Heart Failure participates in the HEART Network which is a network of Editors from most cardiovascular journals. Information is exchanged between Editors on a regular basis. The network has recently approved a common ethics standard.

Its purpose is to ensure transparency and honesty in the scientific process that promotes ethical conduct in performance and publication of research.

The following will be considered as parts of this process:

a. Disclosure of potential conflicts of interest for all involved in the performance of research and in the evaluation and publication process of a manuscript. Relevant relationships with commercial interests should be disclosed according to the guidelines of the journal's sponsoring society, or, when no such guidelines exist, according to those of the AHA, ACC, or ESC.

b. Establish thorough review processes particularly alert to discovering scientific fraud and data falsification, redundant or duplicate publication, and plagiarism, and to adopt a uniform standard of dealing with authors guilty of fraudulent practices.

c. To maintain confidentiality and embargos where appropriate.

d. To create uniform criteria to establish authorship. To qualify for authorship, individuals must have made substantial contributions to the intellectual content of the paper in at least one of the following areas: conceived and designed the research, acquired the data, analysed and interpreted the data, performed statistical analysis, handled funding and supervision, drafted the manuscript, or made critical revision of the manuscript for important intellectual content. Authors must give final approval of the version to be submitted and any revised version to be published. For multi-centre trials, individuals who accept direct responsibility for the manuscript should fully meet the criteria for authorship defined above and contributors not meeting these criteria should be acknowledged.

e. Avoidance of false claims of ownership, priority, by attention to previous publications.

f. Avoidance of excessive claims of benefits of a product/technique, in the publication as well as with news media.

g. Noting compliance with institutional review board requirements and, when appropriate, approved laboratory procedures for animal research, and that the research conforms to the ethical standards of the Declaration of Helsinki, the Geneva Declaration, the Belmont Report, and Good Clinical Practices from the FDA, and the submission conforms to the International Committee of Medical Journal Editors (ICMJE): Uniform Requirements for Manuscripts Submitted to Biomedical Journals: writing and editing for biomedical publication (Haematologica 2005; 89:264).

PRE-SUBMISSION

1. Editorial Review and Acceptance

The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are double-blind peer reviewed by two anonymous reviewers and the Editor. Final acceptance or rejection rests with the Editorial Board, who reserves the right to refuse any material for publication.

Manuscripts should be in a clear, concise and direct style. Where contributions are judged as acceptable for publication on the basis of content, the Editor and the Publisher reserve the right to modify typescripts to eliminate ambiguity and repetition and improve communication between author and reader. If extensive alterations are required, the manuscript will be returned to the author for revision.

2. Pre-submission Resources
2.1. Author Services

Prior to submission, we encourage you to browse Wiley's Author Resources site, which provides useful information on topics such as preparing your article and digital artwork; publishing ethics; copyright and open access; and how to promote your published work.

2.2. Pre-submission English-language Editing

Authors for whom English is a second language are advised to consider having their manuscript professionally edited before submission to improve the English, and to ensure the paper is clearly written in standard, scientific English language appropriate to the discipline. This can be undertaken by a service such as the Wiley English Language Editing Service, at http://wileyeditingservices.com. Please note that using the Wiley English Language Editing Service does not guarantee that your paper will be accepted by this journal, and all services are paid for and arranged by the author.

3. Manuscript Preparation
3.1. Manuscript Categories and Criteria

The European Journal of Heart Failure accepts the following categories of articles:

Full Length Articles

These should not exceed 3500 words (excluding references, tables and figures) and may include up to a maximum of 6 figures and/or tables and up to 30 references. Full length articles should be divided into the following sections: (1) Title page, (2) Abstract and up to six Keywords, (3) Introduction, (4) Methods, (5) Results, (6) Discussion, (7) Acknowledgements, (8) Funding, (9) Conflict of interest, (10) References, (11) Figure legends, (12) Appendices, (13) Tables, (14) Figures. The Abstract should be divided into the following sections ‘Aims’, ‘Methods and results’ and ‘Conclusion’; it should not exceed 250 words.

Reviews

The European Journal of Heart Failure publishes a limited number of scholarly, comprehensive review papers. Reviews should not exceed 3500 words. They should summarise and critically evaluate research in the subject area, and should discuss implications for the future. Reviews have unstructured abstracts with no headings, which should not exceed 250 words and may include up to 45–50 references. Please see below for systematic reviews.

Systematic Reviews

These reviews should follow the format of full length articles (refer to the section, ‘Full Length Articles’). These should be submitted as a full length article during the submission process.

Editorials

All editorials should be limited to 1500 words (excluding references), with a maximum of 15 references. They do not require an abstract and may include one table and/or one figure. In particular, the addition of one figure would be welcome and could add to the understanding and attractiveness of the article. The following different categories of editorials may be considered:

  • Editorial comment. Written upon invitation by the Editor, it is a comment to a research article and should discuss its results, compare them with the current literature and give a personal interpretation of the study.
  • Viewpoint. This is a commentary on a topical item. It may be invited or not. When we receive more viewpoints regarding a similar topic they may be gathered under the category of “Different viewpoints” in the index page. However, their labelling will remain “viewpoint” in the title page so that they may be considered alone.
  • Opinion Piece. This has to be written by one single author and have possibly controversial content and opinions.
  • In the News. This is a single author comment on recent event or trial.
  • From opinion to evidence. This is an expert opinion and can be written by multiple authors. It must be based on facts and be evidence based. Differently from the other categories of editorials, it may reach 2000 words and 30 references.

Short Reports

These reports should not exceed 1500 words and should comprise a Background section (≈100 words), Aims (≈50 words), Methods (≈300 words), Results (300 words) and Conclusion (250 words). The editorial team reserves the right to decide which of the tables/figures submitted are necessary. A structured abstract not exceeding 250 words is also required for Internet purposes.

Letters to the Editor

Letters to the Editor may regard comments to an article published in our journal in the previous months. These letters should have a maximum of 3 authors, should not exceed 400 words and have a maximum of 5 references, including one reference to the article that they are about. We may ask for a reply to the authors of the original article and the letter and its reply be published together.

Research Letters

Letters based on original research findings are also allowed. The letter may include up to 1000 words, including a maximum of 8 references, and one figure and/or Table. Research letters should have no abstract and no sub-headings. However, a short description of methods, results and conclusions is required.

Case Reports

These reports should not exceed 1200 words. Case reports should include an unstructured Abstract with no subheadings (not exceeding 100 words), an Introduction, a Description of the case(s) under the heading, ‘Case Report’ and a Discussion of the findings in the context of current practice.

Study Design

These should not exceed 3500 words (excluding references, tables, and figures) and may include up to a maximum of 6 figures and/or tables and up to 30 references. Study design papers should be divided into the following sections: (1) Title page, (2) Abstract and up to six Keywords, (3) Introduction, (4) Study Design, (5) Discussion, (6) Acknowledgements, (7) Funding, (8) Conflict of Interest, (9) References, (10) Figure legends, (11) Appendices, (12) Tables, (13) Figures. The Abstract should be divided into the following sections ‘Aims’, ‘Methods’, and ‘Conclusion’; it should not exceed 250 words.

Book Reviews

Book reviews may include up to 800 words, including a maximum of 3 references. They should have no abstract and no sub-headings.

3.2. Manuscript Format and Structure

General Format

Prepare your manuscript text using a Word processing package (save in .doc or .rtf format). Submissions of text in the form of PDF files are not permitted. Manuscripts should be double-spaced, including text, tables, legends and references.

Number each page. Please avoid footnotes; use instead, and as sparingly as possible, notes within brackets. Enter text in the style and order of the journal. Type references in the correct order and style of the journal. Type unjustified, without hyphenation, except for compound words (where two words are joined to form a new word e.g. end-systolic, non-infarcted). Type headings in the style of the journal. Use the TAB key once for paragraph indents. Where possible use Times New Roman for the text font and Symbol for Greek and special characters. Use the word processing formatting features to indicate bold, italic, Greek, maths, superscript and subscript characters. Clearly identify unusual symbols and Greek letters. Differentiate between the letter O and zero; the letters I and l; and the number 1.

Check the final copy of your paper carefully, as any spelling mistakes and errors may be translated into the typeset version.

Style and Spelling

Oxford English spelling should be used. Authors whose first language is not English are requested to have their manuscripts checked carefully before submission. This will help expedite the review process and avoid confusion.

Abbreviations

Abbreviations of standard SI units of measurement only should be used.

Ethics

Declaration of Helsinki: The authors should state their study complies with the Declaration of Helsinki, that the locally appointed ethics committee has approved the research protocol and that informed consent has been obtained from the subjects (or their guardians).

ARRIVE Guidelines: The contribution of animal research in enabling better health for man and animals is incontrovertible and EJHF is committed to the publication of research studies which use animal models, but demands the same rigorous attention to detail as in clinical trials. Failure to describe research methods and to report results appropriately has scientific and ethical implications for the entire research process and the reputation of those involved in it.

Experiments involving animals should be appropriately designed, correctly analysed and then transparently reported, to both increase the validity of the results, and maximise the scientific gain. A minimum amount of relevant information must be included in manuscripts published in this journal to ensure that the methods and results of a study can be reviewed, analysed and repeated. EJHF will therefore refer to the ARRIVE (Animals in Research: Reporting In Vivo Experiments) Guidelines as the basis for the process of reviewing manuscripts of research involving animals.

These guidelines were generated by The National Centre for the Replacement, Refinement and Reduction of Animals in Research, which is an independent scientific organisation, established by the UK Government, in consultation with scientists, statisticians, journal editors and research funders.

DNA Sequences and GenBank Accession Number

For each and every gene accession number cited in an article, authors should type the accession number in bold, underlined text. Letters in the accession number should always be capitalised. Example: (GenBank accession nos. AI631510, AI631511, AI632198 and BF223228), a B-cell tumor from a chronic lymphatic leukemia (GenBank accession no. BE675048), and a T-cell lymphoma (GenBank accession no. AA361117).

3.3. Parts of the Manuscript

Title Page

The title page should include the following: (1) the title, (2) the name(s) of authors, (3) the institution(s) where work was performed, (4) the position, institution and location of all authors, (5) the telephone number, fax number and e-mail address of the corresponding author, (6) the institutional affiliations of the authors (including corporate appointments) should be acknowledged in a footnote, (7) total words count.

Abstract and Keywords

All abstracts may not contain more than 250 words and should be submitted as a separate file. The abstract should be formatted with the following heading: (1) Aims, (2) Methods and Results, (3) Conclusion.

A maximum of six keywords may be submitted.

Introduction

This section should provide a rationale for conducting the study within the context of previous work by other authors.

Methods

This section should be sufficiently detailed to enable repetition of the study by other investigators. If pertinent, the section may be divided into headed subsections. For animal studies, this section should contain a statement that, “The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1985)”. Human studies should contain a statement that, “The investigation conforms with the principles outlined in the Declaration of Helsinki” (Br Med J 1964; ii: 177). In addition details of the ethics committee approval procedures and a statement that all subjects gave written informed consent to participate in the study should be included.

Results

If pertinent, the section may be divided into headed subsections. For presentation of data, figures are preferred to tables. Data should not be duplicated in both figures and tables. Extensive numerical data should be presented in legends to the figures rather than in the main body of text. SI units should be used throughout.

Discussion

Four manuscript pages should in general be enough to compare and interpret the findings of the study with regard to previous work by (other) authors. This section should also contain 1–4 paragraphs dealing with topics that are beyond the scope of the study. Limitations to the study should also be discussed.

Figures

General information about graphics:

• All figures should be submitted as separate files.

• Supply figures at final size widths: 84 mm (single column), 176 mm (double column) or 125 mm (intermediate), and containing all parts.

• Label parts clearly using capital letters (e.g. A, B, C etc.).

• Use sans serif, Type 1/OpenType/TrueType fonts for labels (preferably Arial), and Times (New) Roman if serif fonts are required.

• Ensure all lettering/lines are clear and that photographic images are neither blurred nor fuzzy.

• Ensure that all figures are clearly labelled and match the sequence in the text.

• Submit either PDF/EPS (line art) or TIFF (halftone/photographs) files only.

• PDF/EPS files should be saved with fonts embedded (and with a TIFF preview if possible).

• Black and white photographic images should be supplied as 'grayscale'.

• Colour images should be supplied as RGB (not CMYK).

• For scanned images, the scanning resolution (at final image size, see above for a guide to sizes) should be as follows to ensure adequate reproduction:

  • line art, 600 dpi
  • halftones (including gel photographs), 300 dpi
  • figures containing both halftone and line images, 600 dpi

• All scanned images embedded into other applications should be scanned at the recommended resolutions. (e.g., a scanned image placed embedded in a MS Word or PowerPoint document).

• Multipart figures should be supplied in the final layout in one file. If the parts are supplied separately, the individual parts should be named clearly with labels in the filenames.

To facilitate the production of quality published graphics, we recommend that authors generate their graphics in software packages incorporating either a Save As or an Export to TIFF/EPS/PDF function (eg.: Adobe Illustrator, Deneba Canvas, CorelDRAW, Adobe Photoshop). EPS files can be produced from other applications, e.g. PowerPoint, but results can be unpredictable (e.g. fonts and shading may not be converted correctly, lines may go missing, dotted lines may become solid).

If an author has difficulty in creating TIFF/EPS/PDF from their native document, they may provide the original documents in their native formats such as PowerPoint, Word, or Excel file. Our typesetters are able to convert/export the native document files from most applications to a standard format for further processing.

For further details, see the Wiley Electronic Graphics standards and information on preparing electronic graphics.

Figure Legends

These should be on a separate, numbered page, and grouped under the heading "Legends". Define all symbols and abbreviations used in the figure. Common abbreviations and others in the preceding text should not be redefined in the legend.

Colour Figures

The European Journal of Heart Failure does not charge for colour figures.

Tables

Tables should be typed with double spacing, but minimising redundant space, and each should be placed on a separate sheet. Tables should be submitted, wherever possible, in a portrait, as opposed to landscape, layout. Each Table should be numbered in sequence using Arabic numerals. Tables should also have a title above and an explanatory footnote below. All abbreviations used should be defined in the footnote. NB: tables must be submitted in an editable format, such as Excel or Word, and not embedded as an image or presented as an image file.

Permissions

If any figures are to be duplicated from previously published work, written permission must be obtained both from the publisher and the author, and a credit line giving the source added to the relevant figure legend. If text material (250 to 300 words) is to be reproduced from published sources, written permission is required from both publisher and author. For shorter quotations, it is sufficient to add a bibliographic credit. The Letters containing the permission for the reproduction of either text or illustrations must be uploaded with the manuscript files. If you have been unable to obtain permission, please indicate this.

Permission Note
This should list any material (Figures, Tables and/or large amounts of text) that has been previously published. Permissions from the previous publisher/copyright holder should be provided, or alternatively, if all material is original to this submission, then a word document stating this fact should be uploaded with your submission.

Acknowledgements

Substantive contributions of individuals should be noted in the Acknowledgements, positioned before the Conflict of Interest statement.

Conflicts of Interest

All authors must make a formal statement indicating any potential conflicts of interest that might constitute an embarrassment to any of the authors if it were not to be declared and were to emerge after publication. Such conflicts might include, but are not limited to, shareholding in or receipt of a grant or consultancy fee from a company whose product features in the submitted manuscript or which manufactures a competing product. The statement should be positioned before the list of references. If there are no conflicts of interest, please insert the wording, ‘Conflicts of Interest: none declared’. European Journal of Heart Failure uses the ICMJE Conflicts of Interest disclosure form, and requests that each author submits a completed form along with the submission.

References

References should be identified in the text by Arabic numerals and numbered in the order cited. All references should be compiled at the end of the article in the Vancouver style, except that ALL authors should be listed.

Complete information should be given for each reference including the title of the article, abbreviated journal title and page numbers.

Personal communications, manuscripts in preparation and other unpublished data should not be cited in the reference list but may be mentioned in parentheses in the text. Authors should get permission from the source to cite unpublished data. Titles of journals should be abbreviated in accordance with Index Medicus (see list printed annually in the January issue of Index Medicus). If a journal is not listed in Index Medicus then its name should be written out in full.

We recommend the use of a tool such as EndNote or Reference Manager for reference management and formatting. EndNote reference styles can be searched for here: http://www.endnote.com/support/enstyles.asp. For Reference Manager we recommend using the European Heart Journal reference style which can be searched for here: http://www.refman.com/support/rmstyles.asp.

Article Citation Example:

1. Lainchbury JG, Troughton RW, Frampton CM, Yandle TG, Hamid A, Nicholls MG, Richards AM. NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial. Eur J Heart Fail 2006; 8:532-538.

If an article has been published online but has not yet been given issue or page numbers please use the Digital Object Identifier (doi) number when referencing the article as in the example below:

2. Asger A, Møller JM, Daugaard PC, Kjær SU, Erik S. Effects of phosphodiesterase-5 inhibition by sildenafil in the pressure overloaded right heart. Eur J Heart Fail;doi:10.1016/j.eheart.2008.09.016. Published online ahead of print 12 March 2008.

Chapter Citation Example:

3. Nichols WW, O'Rourke MF. Aging, high blood pressure and disease in humans. In: Arnold E, ed. McDonald's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles. 3rd ed. London/Melbourne/Auckland: Lea and Febiger; 1990. p. 398-420.

Website Citation Example:

4. Panteghini M. Recommendations on use of biochemical markers in acute coronary syndrome: IFCC proposals. eJIFCC 14. http://www.ifcc.org/ejifcc/vol14no2/1402062003014n.htm (28 May 2004).;

where the date in parenthesis refers to the access date.

Supporting Information

Supporting information is not essential to the article but provides greater depth and background and may include tables, figures, videos, datasets, etc. This material should be submitted at the same time as the main manuscript, and will appear online, without editing or typesetting. Guidelines on how to prepare this material and which formats and file sizes are acceptable can be found at http://authorservices.wiley.com/bauthor/suppmat.asp.

Please note that the provision of supplementary material is not encouraged as a general rule. It will be assessed critically by reviewers and editors and will only be accepted if it is essential.

Statistics

All manuscripts selected for publication will be reviewed for the appropriateness and accuracy of the statistical methods used and the interpretation of statistical results. All papers submitted should provide in their Methods section a subsection detailing the statistical methods, including the specific method used to summarize the data, the methods used to test their hypothesis testing and (if any) the level of significance used for hypothesis testing.

Sources of Funding

Details of all funding sources for the work in question should be given in a separate section entitled ‘Funding’. This should appear before the ‘Acknowledgements’ section.

The following rules should be followed:

  • The sentence should begin: ‘This work was supported by …’
  • The full official funding agency name should be given, i.e. ‘the National Cancer Institute at the National Institutes of Health’ or simply ‘National Institutes of Health’ not ‘NCI’ (one of the 27 subinstitutions) or ‘NCI at NIH’ (full RIN-approved list of UK funding agencies)
  • Grant numbers should be complete and accurate and provided in brackets as follows: ‘[grant number ABX CDXXXXXX]’
  • Multiple grant numbers should be separated by a comma as follows: ‘[grant numbers ABX CDXXXXXX, EFX GHXXXXXX]’
  • Agencies should be separated by a semi-colon (plus ‘and’ before the last funding agency)
  • Where individuals need to be specified for certain sources of funding the following text should be added after the relevant agency or grant number ‘to [author initials]’.

An example is given here: ‘This work was supported by the National Institutes of Health [P50 CA098252 and CA118790 to R.B.S.R.] and the Alcohol & Education Research Council [HFY GR667789]’.

SUBMISSION OF MANUSCRIPTS

The European Journal of Heart Failure uses a web-based submission and review system at http://www.editorialmanager.com/eurjhf/. Online submission facilitates the submission of manuscripts from authors and streamlines the reviewing and publication process.

Authors may send queries concerning the submission process to ejhf.editorialoffice@wiley.com. For enquiries about the review process and journal procedures, the editorial office can be contacted at ejhf.editorialoffice@wiley.com or +39 030 338 4130. As a matter of policy, the status of documents will not be discussed by telephone.

Once you have prepared your manuscript according to the section, ‘3. PRE-SUBMISSION’, please go to the online submission system by clicking here. First-time users must click ‘Register’ on the navigation menu at the top of the screen. The system will send an automatic e-mail with your user name and password. Detailed guidelines for authors and reviewers are available at the submission site.

4. Submission Requirements
Each submission must include a conflicts of interest statement, and be accompanied by a covering letter; and ICMJE Conflicts of Interest disclosure forms and EJHF Author Contribution Forms from each author.
4.1. Covering Letter

The covering letter should include the following:

  1. a declaration that ‘the manuscript, or part of it, has neither been published (except in the form of abstract or thesis) nor is currently under consideration for publication by any other journal’;
  2. an explanation as to why your paper would be of particular interest to the readers of the European Journal of Heart Failure;
  3. a statement declaring that all named authors have seen and approved the final version of the manuscript.
4.2. Conflict of Interest

When first submitting, all authors must make a formal statement at the time of submission indicating any potential conflict of interest that might constitute an embarrassment to any of the authors if it were not to be declared and were to emerge after publication. Such conflicts might include, but are not limited to, shareholding in or receipt of a grant or consultancy fee from a company whose product features in the submitted manuscript or which manufactures a competing product.

European Journal of Heart Failure follows the guidelines of the International Committee of Medical Journal Editors. A conflict of interest statement must be included in the manuscript after any ‘Acknowledgements’ and ‘Funding’ sections. If there is no conflict of interest, authors must include ‘Conflict of Interest: none declared’. Submissions that do not include this section will not be sent for peer review.

POST-ACCEPTANCE

5. Author Services

Online production tracking is available for your article through Wiley Blackwell’s Author Services. Author Services enables authors to track their article, once it has been accepted, through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated e-mails at key stages of production. The corresponding author will receive a unique link that enables them to register and have their article automatically added to the system. Please ensure that a complete e-mail address is provided when submitting the manuscript. Visit http://authorservices.wiley.com/bauthor/default.asp for more details on online production tracking and for a wealth of resources including FAQs and tips on article preparation, submission and more.

6. Copyright and OnlineOpen

If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.

For Authors Signing the Exclusive License Agreement

If the OnlineOpen option is not selected the corresponding author will be presented with the exclusive license agreement to sign. The terms and conditions of the exclusive license agreement can be previewed below:

Terms and conditions. Please do not complete this PDF until you are prompted to login into Author Services as described above.

Note to Contributors on Deposit of Accepted Version
Funder Arrangements

Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a repository after an embargo period. Details of funding arrangements are set out at the following website: http://www.wiley.com/go/funderstatement. Please contact the Journal production editor if you have additional funding requirements.

Institutions

Wiley has arrangements with certain academic institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: http://www.wiley.com/go/funderstatement.

For Authors Choosing OnlineOpen

If the OnlineOpen option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):

Creative Commons Attribution Non-Commercial License OAA

Creative Commons Attribution Non-Commercial -NoDerivs License OAA

To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html.

If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with Wellcome Trust and Research Councils UK requirements. For more information on this policy and the Journal’s compliant self-archiving policy please visit: http://www.wiley.com/go/funderstatement.

For RCUK and Wellcome Trust authors click on the link below to preview the terms and conditions of this license:

Creative Commons Attribution License OAA

To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html.

7. Proof Corrections

The corresponding author will receive an e-mail alert containing a link to a website. A working e-mail address must therefore be provided for the corresponding author. The proof can be downloaded as a PDF (portable document format) file from this site.

Acrobat Reader will be required in order to read this file. This software can be downloaded (free of charge) from the Adobe website. This will enable the file to be opened, read on screen, and any corrections to be added in. Further instructions will be sent with the proof.

8. Early View (Online Publication Prior to Print)

Early View articles are complete full-text articles published online in advance of their publication in a printed issue. Early View articles are the version of record and are complete and final. They have been fully reviewed, revised and edited for publication, and the authors’ final corrections have been incorporated. As they are in final form, no changes can be made after online publication. Early View articles are given a Digital Object Identifier (DOI), which allows the article to be cited and tracked before it is allocated to an issue. After print publication, the DOI remains valid and can continue to be used to cite and access the article.

9. Author Material Archival Policy

Please note that unless specifically requested, Wiley Blackwell Publishing will dispose of all hardcopy or electronic material submitted two months after publication. If you require the return of any material submitted, please inform the editorial office or production editor as soon as possible.

10. Offprints and Extra Copies

A PDF offprint of the online published article will be provided free of charge to the corresponding author, and may be distributed subject to the Publisher's terms and conditions. Additional paper offprints may be ordered online. Please click on the following link, fill in the necessary details and ensure that you type information in all of the required fields: http://offprint.cosprinters.com/cos.

If you have queries about offprints please e-mail: offprint@cosprinters.com.

OTHER INFORMATION

11. Online

Visit the European Journal of Heart Failure home page at http://wileyonlinelibrary.com/journal/ejhf for more information, and Wiley Online Library’s web pages for submission guidelines and digital graphics standards. European Journal of Heart Failure is also available online via Wiley Online Library at http://wileyonlinelibrary.com.


SEARCH

SEARCH BY CITATION